Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Biotechnology

Healthcare
$0.18 +2.06%

+$0.00 today

Market cap
$70.43M
Beta
1.29
P/E (TTM)
-0.5
EPS (TTM)
-$0.32
52W Low $0.10High $0.77

Volume 0.61M

Average 9.53M

SGMO Income Tax Expense

Income taxes recognized for the period, including current and deferred tax.

Sangamo Therapeutics, Inc.NASDAQ: SGMO

Income Tax Expense · Q1 FY2026 · quarter ended Mar 2026

Income tax expense remains negative

Q1 FY2026 income tax expense was $0, compared with $119K a year earlier. Trailing-twelve-month income tax expense was -$687K.

Context

  • Income tax expense amounted to 1.4% of revenue in FY2025, up 1.1 pp from a year earlier.
  • Income tax expense increased in 1 of the last 3 fiscal years.

What to watch

Whether quarterly income tax expense holds near $0 or moves back toward the trailing-twelve-month quarterly average of -$171.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$0+100.0% QoQ
Last fiscal yearDec 2025
-$568K-240.1% YoY
LTMMar 2026
-$687K-370.5% YoY
Income Tax Expense past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter-100.0%——
1 year-240.1%——
3-year CAGR———
5-year CAGR——
10-year CAGR——

Income Tax Expense history

USD · from the income statement

Latest · FY2025
(568K) USD
Year-over-year change
-240.1%

Income Tax Expense vs competitors

How SGMO compares with its peers on the latest reported figures

  • Peers report in different currencies, so income tax expense is compared through growth and share of revenue rather than absolute size.
  • Its year-over-year change of -370.5% is the lowest of 5, against a peer median of +112.5%.
  • Income tax expense amounts to 2.0% of revenue for SGMO, versus a peer median of 0.0%.
SGMO Competitors
Income Tax Expense for SGMO and competitors
Company Period LTM YoY 3-year CAGR% of revenue
OABIOmniAb, Inc.LTM Mar 2026$913K USD+113.3%—3.2%
CCCCC4 Therapeutics, Inc.LTM Mar 2026$121K USD-7.6%—0.3%
CDXSCodexis, Inc.LTM Mar 2026$72K USD+111.8%-44.6%0.1%
MOLNMolecular Partners AGLTM Mar 2026CHF 5K CHF+463.9%——
ARMPArmata Pharmaceuticals, Inc.LTM Mar 2026$0 USD——0.0%
IPHAInnate Pharma S.A.FY2025€0 EUR——0.0%
IMDXInsight Molecular Diagnostics Inc.LTM Mar 2026$0 USD——0.0%
IVVDInvivyd, Inc.LTM Mar 2026$0 USD——0.0%
RANIRani Therapeutics Holdings, Inc.LTM Mar 2026$0 USD——0.0%
MISTMilestone Pharmaceuticals Inc.LTM Mar 2026-$182K USD——10.2%
SGMOSangamo Therapeutics, Inc.LTM Mar 2026-$687K USD-370.5%—2.0%
Peer median (excluding SGMO) —+112.5%-44.6%0.0%

Competitors are the stored peer set for SGMO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue110.7M111.3M176.23M57.8M39.55M
Cost of Revenue012.11M007.6M
Gross Profit110.7M99.19M176.23M57.8M31.95M
Gross Margin100.0%89.1%100.0%100.0%80.8%
Research & Development230.82M249.9M234.06M111.52M112.67M
Selling, General & Admin63.22M62.68M61.17M44.73M34.89M
Operating Expenses294.04M300.47M450.24M161.77M139.95M
Depreciation & Amortization17.64M12.11M22.19M9.36M7.6M
EBITDA(160.35M)(179.74M)(96.8M)(89.09M)(115.9M)
EBITDA Margin-144.9%-161.5%-54.9%-154.1%-293.0%
Operating Income(183.34M)(201.28M)(274.01M)(103.97M)(108M)
Operating Margin-165.6%-180.8%-155.5%-179.9%-273.1%
Interest Income5.35M9.43M11.1M5.86M1.3M
Interest Expense00000
Other Income / Expenses5.35M9.43M11.1M5.86M(15.5M)
Income Before Tax(177.99M)(191.85M)(262.9M)(98.11M)(123.5M)
Pre-Tax Margin-160.8%-172.4%-149.2%-169.7%-312.2%
Income Tax Expense306K429K(5.07M)(167K)(568K)
Net Income(178.29M)(192.28M)(257.83M)(97.94M)(122.93M)
Net Margin-161.1%-172.8%-146.3%-169.4%-310.8%
EPS (Basic)(1.23)(1.25)(1.48)(0.49)(0.44)
EPS (Diluted)(1.23)(1.25)(1.48)(0.49)(0.44)
Weighted Avg Shares144.57M154.35M174.44M201.7M280.19M
Weighted Avg Shares (Diluted)144.57M154.35M174.44M201.7M280.19M

Sangamo Therapeutics, Inc.

NASDAQ:SGMO

Intrinsic Alpha fair value

Locked

Current Price

$0.18

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.